Trevi Historical Balance Sheet
TRVI Stock | USD 2.88 0.04 1.37% |
Trend analysis of Trevi Therapeutics balance sheet accounts such as Other Liabilities of 2.6 K, Net Tangible Assets of 129.8 M, Total Permanent Equity of 0.0 or Noncontrolling Interest In Consolidated Entity of 0.0 provides information on Trevi Therapeutics' total assets, liabilities, and equity, which is the actual value of Trevi Therapeutics to its prevalent stockholders. By breaking down trends over time using Trevi Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Trevi Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Trevi Therapeutics is a good buy for the upcoming year.
Trevi Therapeutics Inventory |
|
Trevi |
About Trevi Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Trevi Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Trevi Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Trevi Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Trevi currently owns. An asset can also be divided into two categories, current and non-current.
Trevi Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Trevi Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Trevi Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Trevi Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Trevi Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Trevi Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Trevi Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most accounts from Trevi Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Trevi Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.As of now, Trevi Therapeutics' Other Current Assets are increasing as compared to previous years. The Trevi Therapeutics' current Total Liabilities is estimated to increase to about 10.6 M, while Total Assets are projected to decrease to under 56.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.9M | 3.5M | 3.4M | 3.2M | Total Assets | 38.5M | 123.0M | 89.4M | 56.3M |
Trevi Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Trevi Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Trevi Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 60.0M | 47.1M | 38.5M | 123.0M | 89.4M | 56.3M | |
Other Current Liab | 3.5M | 3.4M | 3.9M | 3.5M | 3.4M | 3.2M | |
Total Current Liabilities | 5.2M | 5.6M | 12.7M | 13.4M | 5.8M | 7.3M | |
Total Stockholder Equity | 54.5M | 27.3M | 17.1M | 107.5M | 82.5M | 41.7M | |
Other Liab | 325K | 460K | 196K | 3K | 2.7K | 2.6K | |
Net Tangible Assets | 54.5M | 27.3M | 17.1M | 107.5M | 123.6M | 129.8M | |
Retained Earnings | (114.2M) | (147.0M) | (180.9M) | (210.1M) | (239.1M) | (227.2M) | |
Accounts Payable | 1.6M | 2.0M | 2.8M | 2.9M | 1.8M | 1.7M | |
Cash | 57.3M | 45.0M | 36.8M | 12.6M | 32.4M | 31.8M | |
Other Assets | 1.6M | 19K | 759.0 | 334K | 205K | 0.0 | |
Cash And Short Term Investments | 57.3M | 45.0M | 36.8M | 12.6M | 83.0M | 87.1M | |
Net Receivables | 184K | 558K | 265K | 241K | 277.2K | 243.5K | |
Common Stock Total Equity | 101K | 18K | 19K | 60K | 69K | 37.0K | |
Inventory | 1.4M | 1.6M | 895K | (241K) | (277.2K) | (263.3K) | |
Other Current Assets | 77K | 108K | 886K | 2.1M | 4.6M | 4.8M | |
Other Stockholder Equity | 168.7M | 174.2M | 198.0M | 317.6M | 321.6M | 179.7M | |
Total Liab | 5.5M | 19.8M | 21.4M | 15.6M | 6.9M | 10.6M | |
Short Long Term Debt | 5.3M | 0.0 | 5.8M | 7M | 6.3M | 4.2M | |
Total Current Assets | 59.6M | 46.3M | 38.0M | 122.6M | 87.5M | 55.5M | |
Accumulated Other Comprehensive Income | (23K) | (46K) | (60.0M) | (122K) | (29K) | (30.5K) | |
Short Term Debt | 99K | 113K | 6.0M | 7.0M | 612K | 581.4K | |
Common Stock | 18K | 19K | 29K | 60K | 68K | 41.7K | |
Property Plant Equipment | 430K | 330K | 184K | 170K | 195.5K | 201.5K | |
Property Plant And Equipment Net | 430K | 330K | 184K | 194K | 1.6M | 1.6M | |
Net Debt | (57.0M) | (30.8M) | (22.2M) | (3.4M) | (31.1M) | (32.6M) | |
Non Current Assets Total | 449K | 862K | 518K | 399K | 1.9M | 1.9M | |
Non Currrent Assets Other | 19K | 532K | 334K | 205K | 297K | 341.9K | |
Common Stock Shares Outstanding | 11.7M | 18.1M | 22.8M | 64.5M | 99.0M | 104.0M | |
Liabilities And Stockholders Equity | 60.0M | 47.1M | 38.5M | 123.0M | 89.4M | 63.0M | |
Non Current Liabilities Total | 257K | 14.3M | 8.7M | 2.2M | 1.0M | 980.4K | |
Net Invested Capital | 54.5M | 41.2M | 31.6M | 116.6M | 82.5M | 41.6M | |
Property Plant And Equipment Gross | 430K | 330K | 366K | 419K | 1.7M | 1.8M | |
Net Working Capital | 54.4M | 40.7M | 25.2M | 109.2M | 81.7M | 53.8M | |
Capital Stock | 18K | 19K | 29K | 60K | 68K | 39.3K |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.